Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs TransMedics Group Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.24, while TransMedics Group Inc trades at $75.96 (market cap $2.61B). The key difference: Rex Fang & Innovation Equity Premium Income ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| FEPI | TMDX | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $49.54 | $150.42 |
52-Week Low | $38.13 | $61.99 |
Market Cap | — | $2.61B |
Enterprise Value | — | $3.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI trades at $41.40, down 2.45% over the past day, with technical indicators signaling a bearish trend. The ETF generates a high yield through weekly covered call distributions, but its concentrated tech holdings and call-writing strategy cap upside potential while exposing investors to net asset value erosion during market downturns. Recent news highlights its 25% yield appeal but cautions on structural limitations.
Outlook remains cautious due to the ETF's high-risk income strategy; opportunities exist for yield-seeking investors comfortable with capped gains and volatility, but risks include underperformance versus benchmarks and NAV decay in declining markets. Investor sentiment is mixed, balancing high income against long-term growth constraints.
TransMedics (TMDX) trades at $76.89, up 3.08% today, with a bullish technical signal from moving averages. The company reported strong profitability with a 27.04% net income margin and 45.22% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in PAD Aviation aims to expand its organ transplant logistics network in Europe, enhancing its competitive position.
The outlook remains positive with a consensus price target of $108.71, representing 41% upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion investments and competitive threats. Investors should weigh strong long-term growth initiatives against near-term execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
